FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the 11 Best Short-Term Stocks to Invest in.

Amid revenue surges from the existing drugs, Revuforj and Niktimvo in Q2, FDA grants Priority Review for Revuforj’s sNDA.

FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals

A scientist in a laboratory testing a monoclonal antibody for the treatment of cancer.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage oncology company developing innovative cancer therapies through novel combinations and targeted agents in hematological and solid tumors. Operating from its headquarters in Massachusetts, the company has two FDA-approved products, Revuforj (revumenib), a menin inhibitor, and Niktimvo (axatilimab), a monoclonal antibody that blocks the CSF-1 receptor.

The company reported its Q2 financial results on August 4, 2025, where it highlighted $28.6 million in Revuforj net revenue, a 43% growth compared to the first quarter of 2025. Additionally, Niktimvo, in its first full quarter of launch, generated $36.2 million in net revenue, with Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)’s collaboration revenue from it amounting to $9.4 million, and the product already proving profitable for the company.

Additionally, the FDA has granted a Priority Review for Revuforj’s supplemental New Drug Application (sNDA) in relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia, with a PDUFA action date of October 25, 2025. The Priority Review potentially increases the likelihood of approval and improves the company’s outlook among investors.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)’s stock soared 21.45% this week, offering a notable short-term upswing despite a 42.86% annual decline.

While we acknowledge the risk and potential of SNDX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SNDX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.